Role of Hypofractionated Radiotherapy With Concurrent Gemcitabine in Treatment of Urinary Bladder Carcinoma
NCT ID: NCT04812145
Last Updated: 2021-03-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
50 participants
OBSERVATIONAL
2021-04-01
2023-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Estimate local control, relapse free survival, overall survival and bladder preservation rate. Evaluate the toxicity of a modified hypofractionated chemoradiotherapy protocol for patients with invasive bladder cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery
NCT00777491
Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy
NCT02145390
Chemoradiotherapy for Recurrent T1G3 Bladder Cancer
NCT03274284
Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC
NCT06120374
Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer.
NCT00330499
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Chemoradiation
Hypofractionated radiotherapy with concurrent Gemcitabine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Esraa Mostafa Abdelzaher Mohamed
Principal Investigator
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
1. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2019. CA: a cancer journal for clinicians, 2019. 69(1): p. 7-34. 2. Staerkel,Ro, J.Y., G.A. andAyala, A.G. Cytologic and histologic features of superficial bladder cancer. The Urologic clinics of North America, 1992. 19(3): p. 435-453. 3. Witjes, J.A., T. Lebret, E.M. Compérat, N.C. Cowan, M. De Santis, H.M. Bruins, et al., Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. European urology, 2017. 71(3): p. 462-475. 4. De Santis, M. Bachner , M. Cerveny, et al. Combined chemoradiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma of the urinary bladder and/or in patients ineligible for surgery: a phase I trial. Ann Oncol, 25 (2014), pp. 1789-1794. 5. Kimura, T., H. Ishikawa, T. Kojima, S. Kandori, T. Kawahara, Y. Sekino, et al., Bladder preservation therapy for muscle invasive bladder cancer: the past, present and future. Japanese Journal of Clinical Oncology, 2020. 50(10): p. 1097-1107. 6. Flaig, T.W., P.E. Spiess, N. Agarwal, R. Bangs, S.A. Boorjian, M.K. Buyyounouski, et al., NCCN guidelines insights: bladder cancer, version 5.2018. Journal of the National Comprehensive Cancer Network, 2018. 16(9): p. 1041-1053. 7. Mitin, T., A. George, A.L. Zietman, N.M. Heney, D.S. Kaufman, R.G. Uzzo, et al., Long-term outcomes among patients who achieve complete or near-complete responses after the induction phase of bladder-preserving combined-modality therapy for muscle-invasive bladder cancer: a pooled analysis of NRG Oncology/RTOG 9906 and 0233. International Journal of Radiation Oncology* Biology* Physics, 2016. 94(1): p. 67-74. 8. Mak, K.S., A.B. Smith, A. Eidelman, R. Clayman, A. Niemierko, J.-S. Cheng, et al., Quality of life in long-term survivors of muscle-invasive bladder cancer. International Journal of Radiation Oncology* Biology* Physics, 2016. 96(5): p. 1028-1036. 9. Azria, D., O. Riou, X. Rebillard, S. Thezenas, R. Thuret, P. Fenoglietto, et al., Combined chemoradiation therapy with twice-weekly gemcitabine and cisplatin for organ preservation in muscle-invasive bladder cancer: long-term results of a phase 1 trial. International Journal of Radiation Oncology* Biology* Physics, 2014. 88(4): p. 853-859. 10. Shipley, W.U., G.R. Prout, A.B. Einstein, L.J. Coombs, Z. Wajsman, M.S. Soloway, et al., Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. Jama, 1987. 258(7): p. 931-935. 11. Borut K, Lijana ZK. Phase I study of radiochemothearpy with gemcitabine in invasive bladder cancer. RadiotherOncol 2012;102:412-5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U.Bladder Cancer Radiotherapy
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.